Steve Berman

ACAD SHAREHOLDER DEADLINE TOMORROW: Hagens Berman Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm Now

Retrieved on: 
Thursday, June 17, 2021
Steve Berman, Food and Drug Administration, Hagens

Thereafter, the company repeatedly stated the FDA had not identified any potential review issues and reiterated the drugs efficacy.

Key Points: 
  • Thereafter, the company repeatedly stated the FDA had not identified any potential review issues and reiterated the drugs efficacy.
  • Were focused on investors losses and proving Acadia misled investors by concealing FDA-related review risks for the sNDA, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you are an Acadia investor and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages ChemoCentryx (CCXI) Investors with Losses to Contact the Firm, Application Deadline Approaching in Securities Fraud Action

Retrieved on: 
Thursday, June 17, 2021
Pharmaceutical industry, Steve Berman, Securities fraud, New Drug Application, Health sciences, Health care, Drugs

ChemoCentryx, Inc. (NASDAQ: CCXI) Securities Fraud Class Action:

Key Points: 
  • ChemoCentryx, Inc. (NASDAQ: CCXI) Securities Fraud Class Action:
    The lawsuit focuses on ChemoCentryxs statements about its new drug application (NDA) for its vasculitis drug candidate Avacopan.
  • In addition, the document took issue with the complex trial design and the lack of long-term safety data.
  • Were focused on investors losses and proving ChemoCentryx misled investors about Avacopans efficacy and safety, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys.

EBS INVESTOR DEADLINE TOMORROW: Hagens Berman Encourages Emergent BioSolutions (EBS) Investors with Losses to Contact the Firm Now, Securities Fraud Lawsuit Pending

Retrieved on: 
Thursday, June 17, 2021
Emergent BioSolutions, Steve Berman, Hagens, Emergent, Companies

SAN FRANCISCO, June 17, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, June 17, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now .
  • Were focused on investors losses and proving Emergent lied about its vaccine production capabilities, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you are an Emergent investor and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys.

HAGENS BERMAN Encourages ContextLogic (WISH) Investors with Significant Losses to Contact its Attorneys Now, Securities Fraud Lawsuit Pending

Retrieved on: 
Monday, June 14, 2021
Steve Berman, Initial public offering, Hagens

Specifically, the IPO registration documents touted ContextLogics exponential monthly active user (MAUs) growth, claiming its then 108 million MAUs was a key driver of revenue growth.

Key Points: 
  • Specifically, the IPO registration documents touted ContextLogics exponential monthly active user (MAUs) growth, claiming its then 108 million MAUs was a key driver of revenue growth.
  • Were focused on investors losses and proving ContextLogic overstated MAUs and concealed known trends, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you are a ContextLogic investor and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys.

EBS 6-DAY DEADLINE ALERT: Hagens Berman Encourages Emergent BioSolutions (EBS) Investors to Contact the Firm Before June 18th Deadline in Securities Fraud Action

Retrieved on: 
Saturday, June 12, 2021
Health care, Health, COVID-19 vaccines, Clinical trials, Medical specialties, Adenoviridae, Emergent BioSolutions, Johnson & Johnson COVID-19 vaccine, Steve Berman, Johnson & Johnson, Vaccine

SAN FRANCISCO, June 12, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, June 12, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now .
  • 31, 2021, media reports revealed the company mixed up ingredients for J&Js and AstraZenecas vaccines, contaminating up to 15 million J&J vaccine doses.
  • Were focused on investors losses and proving Emergent lied about its vaccine production capabilities, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys.

HAGENS BERMAN Alerts Danimer Scientific (DNMR) Investors to Securities Fraud Lawsuit, Encourages Investors with Losses to Contact its Attorneys Now

Retrieved on: 
Saturday, June 12, 2021
Steve Berman, Citigroup, Hagens, Economy of New York City, Companies, Banks

SAN FRANCISCO, June 12, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Danimer Scientific, Inc. (NYSE: DNMR) investors with significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, June 12, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Danimer Scientific, Inc. (NYSE: DNMR) investors with significant losses to submit your losses now .
  • 20, 2021, when the Wall Street Journal reported that many claims about Nodax are exaggerated and misleading.
  • Were focused on investors losses and proving Danimer misled investors by greenwashing and misstating its true performance metrics, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys.

HAGENS BERMAN Alerts Aterian (ATER) Investors to Securities Fraud Lawsuit, Encourages Investors with Losses to Contact the Firm Now

Retrieved on: 
Saturday, June 12, 2021
Aterian, Steve Berman, Hagens, Citigroup, Economy of New York City, Companies, Banks

The truth emerged on May 4, 2021, when analyst Culper Research published a scathing report entitled Aterian (ATER): Bought from Felons & Fraudsters, Sold to You.

Key Points: 
  • The truth emerged on May 4, 2021, when analyst Culper Research published a scathing report entitled Aterian (ATER): Bought from Felons & Fraudsters, Sold to You.
  • Were focused on investors losses and proving Aterian misled investors about its acquisitions and the AIMEE platform, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you are an Aterian investor and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys.

HAGENS BERMAN Alerts ChemoCentryx (CCXI) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors with Losses Should Contact the Firm

Retrieved on: 
Saturday, June 12, 2021
Steve Berman, Securities fraud, Citigroup, Hagens, Companies, Economy of New York City, Finance

ChemoCentryx, Inc. (NASDAQ: CCXI) Securities Fraud Class Action:

Key Points: 
  • ChemoCentryx, Inc. (NASDAQ: CCXI) Securities Fraud Class Action:
    The lawsuit focuses on ChemoCentryxs statements about its new drug application (NDA) for its vasculitis drug candidate Avacopan.
  • Were focused on investors losses and proving ChemoCentryx misled investors about Avacopans efficacy and safety, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you are a ChemoCentryx investor and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys.

RMO 3-DAY DEADLINE ALERT: Hagens Berman Encourages Romeo Power (RMO) Investors with Losses to Contact the Firm Before June 15th Deadline in Securities Class Action

Retrieved on: 
Saturday, June 12, 2021
Steve Berman

SAN FRANCISCO, June 12, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Romeo Power, Inc. (NYSE: RMO) investors with significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, June 12, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Romeo Power, Inc. (NYSE: RMO) investors with significant losses to submit your losses now .
  • A securities class action has been filed and certain investors may have valuable claims.
  • The company repeatedly assured investors it had sufficient long-term contracts to supply enough battery cells even in the face of the tight supply.
  • Were focused on investors losses and proving Romeo concealed supply chain risks, said Reed Kathrein, the Hagens Berman partner leading the investigation.

ACAD 6-DAY DEADLINE ALERT: Hagens Berman Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, Deadline Approaching in Securities Class Action

Retrieved on: 
Saturday, June 12, 2021
Steve Berman, Acadia Pharmaceuticals, Hagens, Food and Drug Administration, Health care, Healthcare in the United States, Health

SAN FRANCISCO, June 12, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, June 12, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now .
  • Thereafter, the company repeatedly stated the FDA had not identified any potential review issues and reiterated the drugs efficacy.
  • Were focused on investors losses and proving Acadia misled investors by concealing FDA-related review risks for the sNDA, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys.